Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients
The aim of the study was to investigate the safety of adenosine 5′-triphosphate (ATP) administration at home in pre-terminal cancer patients. Included were patients with cancer for whom medical treatment options were restricted to supportive care, who had a life expectancy of less than 6 months, a W...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer US
2007
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039853/ |
| id |
pubmed-2039853 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-20398532007-10-29 Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients Beijer, Sandra Gielisse, Eric A. R. Hupperets, Pierre S. van den Borne, Ben E. E. M. van den Beuken-van Everdingen, Marieke Nijziel, Marten R. van Henten, Arjen M. J. Dagnelie, Pieter C. Phase III Studies The aim of the study was to investigate the safety of adenosine 5′-triphosphate (ATP) administration at home in pre-terminal cancer patients. Included were patients with cancer for whom medical treatment options were restricted to supportive care, who had a life expectancy of less than 6 months, a World Health Organization performance status 1 or 2, and suffered from at least one of the following complaints: fatigue, anorexia or weight loss >5% over the previous 6 months. Side effects were registered systematically on a standard form according to the National Cancer Institute (NCI) Common Toxicity Criteria. Fifty-one patients received a total of 266 intravenous ATP infusions. Of these, 11 infusions (4%) were given at the lowest dose of 20 μg kg−1 min−1, 85 infusions (32%) at 25–40 μg kg−1 min−1, and 170 (64%) at the highest dose of 45–50 μg kg−1 min−1 ATP. The majority of ATP infusions (63%) were without side effects. Dyspnea was the most common side effect (14% of infusions), followed by chest discomfort (12%) and the urge to take a deep breath (11%). No symptoms of cardiac ischemia occurred in any of the infusions. All side effects were transient and resolved within minutes after lowering the ATP infusion rate. Side effects were most frequent in the presence of cardiac disorders. We conclude that ATP at a maximum dose of 50 μg kg−1 min−1 can be safely administered in the home setting in patients with pre-terminal cancer. Springer US 2007-09-05 2007-12 /pmc/articles/PMC2039853/ /pubmed/17786387 http://dx.doi.org/10.1007/s10637-007-9076-1 Text en © Springer Science+Business Media, LLC 2007 |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Beijer, Sandra Gielisse, Eric A. R. Hupperets, Pierre S. van den Borne, Ben E. E. M. van den Beuken-van Everdingen, Marieke Nijziel, Marten R. van Henten, Arjen M. J. Dagnelie, Pieter C. |
| spellingShingle |
Beijer, Sandra Gielisse, Eric A. R. Hupperets, Pierre S. van den Borne, Ben E. E. M. van den Beuken-van Everdingen, Marieke Nijziel, Marten R. van Henten, Arjen M. J. Dagnelie, Pieter C. Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients |
| author_facet |
Beijer, Sandra Gielisse, Eric A. R. Hupperets, Pierre S. van den Borne, Ben E. E. M. van den Beuken-van Everdingen, Marieke Nijziel, Marten R. van Henten, Arjen M. J. Dagnelie, Pieter C. |
| author_sort |
Beijer, Sandra |
| title |
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients |
| title_short |
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients |
| title_full |
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients |
| title_fullStr |
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients |
| title_full_unstemmed |
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients |
| title_sort |
intravenous atp infusions can be safely administered in the home setting: a study in pre-terminal cancer patients |
| description |
The aim of the study was to investigate the safety of adenosine 5′-triphosphate (ATP) administration at home in pre-terminal cancer patients. Included were patients with cancer for whom medical treatment options were restricted to supportive care, who had a life expectancy of less than 6 months, a World Health Organization performance status 1 or 2, and suffered from at least one of the following complaints: fatigue, anorexia or weight loss >5% over the previous 6 months. Side effects were registered systematically on a standard form according to the National Cancer Institute (NCI) Common Toxicity Criteria. Fifty-one patients received a total of 266 intravenous ATP infusions. Of these, 11 infusions (4%) were given at the lowest dose of 20 μg kg−1 min−1, 85 infusions (32%) at 25–40 μg kg−1 min−1, and 170 (64%) at the highest dose of 45–50 μg kg−1 min−1 ATP. The majority of ATP infusions (63%) were without side effects. Dyspnea was the most common side effect (14% of infusions), followed by chest discomfort (12%) and the urge to take a deep breath (11%). No symptoms of cardiac ischemia occurred in any of the infusions. All side effects were transient and resolved within minutes after lowering the ATP infusion rate. Side effects were most frequent in the presence of cardiac disorders. We conclude that ATP at a maximum dose of 50 μg kg−1 min−1 can be safely administered in the home setting in patients with pre-terminal cancer. |
| publisher |
Springer US |
| publishDate |
2007 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039853/ |
| _version_ |
1611405443755671552 |